Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9819 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| AZD9819 | EXPERIMENTAL | Inhaled suspension |
| Placebo | PLACEBO_COMPARATOR | Inhaled suspension |
| Name | Type | Description |
|---|---|---|
| AZD9819 | DRUG | Inhaled single doses of suspension via SPIRA nebuliser |
| Placebo | DRUG | Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B) |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures * Healthy male and female (non-child bearing potential) subjects aged 18 to 50 years with suitable veins for cannulation or repeated venepuncture. * Have a body mass index (BMI) betw...
AZD9819 is an investigational small molecule being studied in healthy volunteers to assess its safety and tolerability. It is administered as an inhaled dose. The drug is in Phase 1 clinical development and is not approved for any condition.
AZD9819 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy subjects.
AZD9819 is in Phase 1 clinical development. A Phase 1 trial has been completed, which involved 100 healthy volunteers. The drug is investigational and has not received regulatory approval.
AZD9819 has one completed Phase 1 trial, identified as NCT01166698. This was a single-center, double-blind, placebo-controlled study that evaluated single and multiple ascending inhaled doses of AZD9819 in healthy subjects in the United Kingdom.
AZD9819 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial focused on safety and tolerability in healthy volunteers, and the drug has not been authorized for any medical use.